肺炎球菌合并感染及肺炎球菌疫苗接种对新型冠状病毒肺炎临床预后的影响  

Impact of co-infection of streptococcus pneumoniae and pneumococcal vaccination on the clinical outcomes of coronavirus disease 19

作　　者：白云骅[1] 张政[1] 李淑萍[1] Bai Yunhua;Zhang Zheng;Li Shuping(Department of Biological Products,Chaoyang District Center for Disease Prevention and Control of Beijing,Beijing 100020,China)

机构地区：[1]北京市朝阳区疾病预防控制中心生物制品科,北京100020

出　　处：《中华预防医学杂志》2022年第5期659-667,共9页Chinese Journal of Preventive Medicine

摘　　要：由严重急性呼吸综合征冠状病毒2引起的新型冠状病毒肺炎已波及世界各国。肺炎球菌作为常见的社区获得性肺炎病原菌,与新型冠状病毒肺炎具有相似的高危易感人群,合并肺炎球菌感染是导致新型冠状病毒肺炎重症和死亡的关键危险因素。肺炎球菌疫苗接种对降低新型冠状病毒肺炎的发生率及死亡率具有积极的影响。我国肺炎球菌肺炎疫苗接种率较低,对老年、存在慢性基础性疾病等高危人群接种肺炎球菌疫苗或是应对新型冠状病毒肺炎的有效措施之一。Coronavirus disease 19(COVID-19)caused by severe acute respiratory syndrome coronavirus 2 has spread all over the world.Streptococcus pneumoniae as a common pathogen of community-acquired pneumonia shares similar high-risk susceptible populations with COVID-19.Streptococcus pneumoniae co-infection is a key risk factor for severe COVID-19 and death.Pneumococcal vaccination has a beneficial impact on reducing the incidence and mortality of COVID-19.The vaccination rate of streptococcus pneumoniae is still low in China.Streptococcus pneumoniae vaccination may be one of effective strategies in the management of COVID-19 for high-risk population such as the elderly and those who have underlying chronic diseases.

关 键 词：严重急性呼吸综合征冠状病毒2 新型冠状病毒肺炎 肺炎球菌肺炎 疫苗 

分 类 号：R563.1[医药卫生—呼吸系统]